News

VitalStream Offers Continuous Hemodynamic Monitoring Solution Amid IV Fluid Shortage

Caretaker Medical, a pioneer in advanced hemodynamic monitoring technology, is highlighting the critical role of its VitalStream solution in addressing the ongoing IV fluid shortage caused by Hurricane Helene. As healthcare providers face challenges in maintaining continuous blood pressure monitoring due to the limited availability of Baxter IV fluids, VitalStream offers a reliable and innovative alternative.

VitalStream provides continuous hemodynamic monitoring without the need for invasive arterial lines or continuous IV fluid infusion. This groundbreaking technology eliminates the reliance on IV fluids for blood pressure measurement, offering significant advantages during times of supply shortages. By providing real-time insights into a patient’s response to fluids, VitalStream can potentially reduce the overall need for IV fluid administration.

“The IV fluid shortage has created a significant challenge for healthcare providers across the country,” said Johnny Mann, VP Sales and Marketing at Caretaker Medical. “VitalStream offers a valuable solution by enabling continuous hemodynamic monitoring without the need for invasive lines or constant IV fluid infusion. This technology can help ensure patient safety and optimize fluid management during these challenging times.”

Caretaker Medical will be showcasing VitalStream at the upcoming American Society of Anesthesiologists (ASA) Conference in Philadelphia from October 19-21. Attendees will have the opportunity to learn more about this innovative technology and its potential benefits in addressing the current IV fluid shortage.

Learn more here.

Recent News

04/08/2026

Likarda and The Tiny Cargo Company Announce Strategic Partnership to Advance Next-Generation Delivery of Biologics, Peptides and Small Molecules

Likarda, Inc., a leader in hydrogel-based drug delivery technologies, today announced a strategic partnership with Tiny Cargo, an innovator in extracellular vesicle (EV) delivery systems. The collaboration will focus on advancing the delivery of biologics and small molecules by integrating Likarda’s Core-Shell Spherification® (CSS®) platform with Tiny Cargo’s vesicle-based technologies. The partnership is designed to

04/08/2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the closing of an oversubscribed $40 million financing. This brings the total capital raised to date to more than $150 million.

04/02/2026

ATCC Receives New CDC Award to Help Fast-track Diagnostic Tests for Future Disease Outbreaks

TCC has been selected by the Centers for Disease Control and Prevention (CDC) Office of Readiness and Response (ORR) for a new five-year contract to support rapid test development during public health emergencies. The award, valued at up to $148 million (IDIQ contract 75D301-25-R-73207), will help ensure that diagnostic tools can be quickly created, validated,